undamentalytics Newsletter
Sign in

Nuvation Bio Inc. balance sheet

At the end of fiscal 2025, Nuvation Bio Inc. had total assets of $595m, total liabilities of $289m and shareholders' equity of $306m. It held $164m in cash against $52.9m of debt: net cash of $111m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents4336164259
Inventory—01120
Total current assets616526572726
Total assets621541595745
Accounts payable26912
Deferred revenue (current)01189
Total current liabilities14588287
Short-term debt0666
Long-term debt——47243
Total debt0653249
Total liabilities1677289491
Shareholders' equity605464306254
Net debt (negative = net cash)−43−29−111−10
Shares outstanding219m—347m347m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: IBRX vs NUVBABUS vs NUVBBEAM vs NUVBNUVB vs URGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Nuvation Bio Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nuvation Bio Inc.